000168174 001__ 168174
000168174 005__ 20260128154425.0
000168174 0247_ $$2doi$$a10.3399/bjgp12X659295
000168174 0248_ $$2sideral$$a80055
000168174 037__ $$aART-2012-80055
000168174 041__ $$aeng
000168174 100__ $$aCalderón-Larrañaga, A.
000168174 245__ $$aMultimorbidity, polypharmacy, referrals, and adverse drug events: Are we doing things well?
000168174 260__ $$c2012
000168174 5203_ $$aBackground The consequences of multimorbidity include polypharmacy and repeated referrals for specialised care, which may increase the risk of adverse drug events (ADEs).
Aim The objective of this study was to analyse the influence of multimorbidity, polypharmacy, and multiple referrals on the frequency of ADEs, as an indicator of therapeutic safety, in the context of a national healthcare system.
Design and setting This was a multicentre, retrospective, observational study of 79 089 adult patients treated during 2008 in primary care centres.
Method The explanatory patient variables sex, age, level of multimorbidity, polypharmacy, number of primary care physician visits, and number of different specialties attended were analysed. The response variable was the occurrence of ADEs. Logistic regression models were used to identify associations among the analysed variables.
Results The prevalence of individuals with at least one ADE was 0.88%. Multivariate analysis identified the following variables as risk factors for the occurrence of ADE in descending order of effect size: multimorbidity level (odds ratio [OR]Veryhigh/Low = 45.26; ORHigh/Low = 17.58; ORModerate/Low = 4.25), polypharmacy (OR = 1.34), female sex (OR = 1.31), number of different specialties (OR = 1.20), and number of primary care physician visits (OR = 1.01). Age, however, did not show statistical significance (OR = 1.00; 95% confidence interval = 0.996 to 1.005).
Conclusion The results of this study demonstrate that multimorbidity is strongly related to the occurrence of ADEs, insofar as it requires the intervention of multiple specialties and the prescription of multiple medications. Further research should shed light on the causal pathway between multimorbidity and increased risk of adverse events.
000168174 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000168174 590__ $$a2.034$$b2012
000168174 591__ $$aPRIMARY HEALTH CARE$$b3 / 18 = 0.167$$c2012$$dQ1$$eT1
000168174 591__ $$aMEDICINE, GENERAL & INTERNAL$$b41 / 153 = 0.268$$c2012$$dQ2$$eT1
000168174 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000168174 700__ $$aPoblador-Plou, B.
000168174 700__ $$0(orcid)0000-0003-2580-2002$$aGonzález-Rubio, F.$$uUniversidad de Zaragoza
000168174 700__ $$0(orcid)0000-0003-2928-6623$$aGimeno-Feliu, L.$$uUniversidad de Zaragoza
000168174 700__ $$0(orcid)0000-0001-9466-3902$$aAbad-Díez, J. M.$$uUniversidad de Zaragoza
000168174 700__ $$0(orcid)0000-0002-5704-6056$$aPrados-Torres, A.$$uUniversidad de Zaragoza
000168174 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000168174 7102_ $$11008$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Medic.Prevent.Salud Públ.
000168174 773__ $$g62, 605 (2012), e821-e826$$pBr. j. gen. pract.$$tBRITISH JOURNAL OF GENERAL PRACTICE$$x0960-1643
000168174 8564_ $$s80543$$uhttps://zaguan.unizar.es/record/168174/files/texto_completo.pdf$$yVersión publicada
000168174 8564_ $$s2982251$$uhttps://zaguan.unizar.es/record/168174/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000168174 909CO $$ooai:zaguan.unizar.es:168174$$particulos$$pdriver
000168174 951__ $$a2026-01-28-15:42:22
000168174 980__ $$aARTICLE